BiotechTube
Resolve Therapeutics

Resolve Therapeutics

Seattle, United States· Est.
resolvetherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Resolve Therapeutics is pioneering a novel therapeutic approach that targets extracellular RNA and DNA as a fundamental driver of inflammation. Its lead asset, RSLV-132, is an Fc-fusion nuclease in Phase 2 trials for Sjögren's disease, with prior clinical data generated in lupus and Long COVID. The company is leveraging its platform to address both chronic autoimmune conditions and acute inflammatory settings like polytrauma, positioning itself in a high-unmet-need market with a potentially differentiated, non-immunosuppressive mechanism.

Autoimmune DiseasesInflammatory DiseasesCritical Care

Technology Platform

Fully-human biologic Fc-fusion nuclease platform combining RNases/DNases with an antibody Fc domain to enzymatically degrade extracellular nucleic acids (cfRNA, cfDNA, NETs) that drive inflammation.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The primary opportunity is addressing the large unmet need in Sjögren's disease, a chronic autoimmune condition with no approved disease-modifying therapies.
A secondary, potentially larger opportunity lies in applying the platform to acute inflammatory conditions like polytrauma and stroke, where modulating the initial inflammatory trigger could improve survival and outcomes in critical care settings.

Risk Factors

Key risks include clinical trial failure for the lead asset RSLV-132 in Sjögren's, which would challenge the core platform hypothesis.
The novel mechanism, while differentiating, carries regulatory and adoption risk as a first-in-class approach.
As a private, pre-revenue company, Resolve also faces significant financing risk to advance its pipeline.

Competitive Landscape

Competition in Sjögren's and lupus includes broad immunosuppressants and a few targeted biologics, but no therapies directly targeting extracellular nucleic acids. In the broader field of NETs and nucleic acid clearance, Resolve faces emerging competition from other biotechs and academic efforts. Its primary competitive advantage is the clinical-stage validation of its specific Fc-RNase fusion approach.

More companies in Biologics / Biosimilars →More companies in United States →